
Erasca upgraded to Buy as ERAS-0015 shows strong cancer trial results and patent issues ease.
Erasca has been upgraded from Hold to Buy following promising early trial results for its drug ERAS-0015, which showed unconfirmed response rates of 50% in pancreatic cancer and 64% in lung cancer. The company plans three registrational trials by 202...




